QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

Immuneering (IMRX) Competitors

$1.80
+0.03 (+1.69%)
(As of 04:00 PM ET)

IMRX vs. FIXX, SCYX, RPHM, VAXX, GANX, KZR, GMTX, JAGX, DARE, and APLM

Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Homology Medicines (FIXX), SCYNEXIS (SCYX), Reneo Pharmaceuticals (RPHM), Vaxxinity (VAXX), Gain Therapeutics (GANX), Kezar Life Sciences (KZR), Gemini Therapeutics (GMTX), Jaguar Health (JAGX), Daré Bioscience (DARE), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.

Immuneering vs.

Immuneering (NASDAQ:IMRX) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 31.3% of Homology Medicines shares are owned by institutional investors. 23.0% of Immuneering shares are owned by insiders. Comparatively, 16.1% of Homology Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immuneering has a net margin of 0.00% compared to Homology Medicines' net margin of -4,779.31%. Immuneering's return on equity of -52.49% beat Homology Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -52.49% -47.63%
Homology Medicines -4,779.31%-102.52%-74.91%

Homology Medicines received 102 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 64.43% of users gave Homology Medicines an outperform vote while only 60.53% of users gave Immuneering an outperform vote.

CompanyUnderperformOutperform
ImmuneeringOutperform Votes
23
60.53%
Underperform Votes
15
39.47%
Homology MedicinesOutperform Votes
125
64.43%
Underperform Votes
69
35.57%

In the previous week, Immuneering had 6 more articles in the media than Homology Medicines. MarketBeat recorded 6 mentions for Immuneering and 0 mentions for Homology Medicines. Immuneering's average media sentiment score of 0.59 beat Homology Medicines' score of 0.00 indicating that Immuneering is being referred to more favorably in the media.

Company Overall Sentiment
Immuneering Positive
Homology Medicines Neutral

Immuneering has higher earnings, but lower revenue than Homology Medicines. Immuneering is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuneering$320K161.96-$53.47M-$1.89-0.94
Homology Medicines$1.16M0.00-$112.96M-$1.96N/A

Immuneering currently has a consensus target price of $13.50, indicating a potential upside of 662.71%. Homology Medicines has a consensus target price of $0.75, indicating a potential upside of ∞. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than Immuneering.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Homology Medicines
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Immuneering has a beta of -0.89, indicating that its stock price is 189% less volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.

Summary

Immuneering beats Homology Medicines on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRX vs. The Competition

MetricImmuneeringPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$54.47M$6.51B$4.79B$7.48B
Dividend YieldN/A3.13%2.98%4.00%
P/E Ratio-0.948.07191.6415.38
Price / Sales161.96308.692,563.7984.02
Price / CashN/A20.2946.8734.89
Price / Book0.575.444.584.19
Net Income-$53.47M$143.31M$103.64M$214.15M
7 Day Performance-15.71%-5.69%-3.80%-3.31%
1 Month Performance-31.13%-8.04%-5.31%-3.82%
1 Year Performance-86.31%-5.50%7.35%3.74%

Immuneering Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FIXX
Homology Medicines
1.4934 of 5 stars
$0.93
+0.8%
$0.75
-19.8%
N/A$54.33M$1.16M-0.487
SCYX
SCYNEXIS
2.8683 of 5 stars
$1.41
-4.1%
$15.00
+963.8%
-56.6%$53.23M$140.14M1.0736Positive News
RPHM
Reneo Pharmaceuticals
0.8677 of 5 stars
$1.65
-0.6%
$18.14
+999.2%
-78.6%$55.14MN/A-0.6555Gap Down
VAXX
Vaxxinity
1.1839 of 5 stars
$0.44
-2.2%
$7.00
+1,491.6%
-78.1%$55.75M$70,000.00-0.9887Gap Up
GANX
Gain Therapeutics
3.3122 of 5 stars
$3.16
+2.3%
$8.33
+163.7%
-35.5%$51.26M$50,000.00-1.8528Positive News
KZR
Kezar Life Sciences
3.9767 of 5 stars
$0.78
-3.7%
$11.00
+1,304.7%
-68.1%$57.01M$7M-0.5658Short Interest ↑
GMTX
Gemini Therapeutics
0 of 5 stars
$30.52
-4.1%
N/A+18.2%$58.49MN/A-30.5231High Trading Volume
JAGX
Jaguar Health
0 of 5 stars
$0.18
+50.7%
N/A-70.9%$49.25M$9.76M0.0060News Coverage
Gap Down
High Trading Volume
DARE
Daré Bioscience
1.7461 of 5 stars
$0.48
flat
$6.00
+1,137.4%
-70.8%$48.77M$2.81M-1.4325Analyst Downgrade
Gap Down
APLM
Apollomics
0.9429 of 5 stars
$0.54
-3.6%
$5.00
+825.8%
-91.0%$48.34M$1.22M0.0045

Related Companies and Tools

This page (NASDAQ:IMRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners